Matthew P. Cheng

11.2k total citations · 2 hit papers
113 papers, 2.6k citations indexed

About

Matthew P. Cheng is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Matthew P. Cheng has authored 113 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Infectious Diseases, 48 papers in Epidemiology and 16 papers in Clinical Biochemistry. Recurrent topics in Matthew P. Cheng's work include SARS-CoV-2 and COVID-19 Research (24 papers), COVID-19 Clinical Research Studies (18 papers) and Bacterial Identification and Susceptibility Testing (16 papers). Matthew P. Cheng is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (24 papers), COVID-19 Clinical Research Studies (18 papers) and Bacterial Identification and Susceptibility Testing (16 papers). Matthew P. Cheng collaborates with scholars based in Canada, United States and United Kingdom. Matthew P. Cheng's co-authors include Cédric P. Yansouni, Todd C. Lee, Jesse Papenburg, Caroline Quach, Guillaume Butler‐Laporte, Sanjat Kanjilal, Michaël Desjardins, Michael Libman, Sabine Dittrich and Emily G. McDonald and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Matthew P. Cheng

104 papers receiving 2.6k citations

Hit Papers

Phase 1 randomized trial of a plant-derived virus-like pa... 2021 2026 2022 2024 2021 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
    2021 214 citations Brian J. Ward, Philipe Gobeil et al. Nature Medicine profile →
  2. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis
    2022 150 citations Guillaume Butler‐Laporte, Emily G. McDonald et al. profile →

Peers

Matthew P. Cheng
Nicasio Mancini Italy
Harald H. Kessler Austria
Miki Nagao Japan
Hee‐Chang Jang South Korea
Jeroen J. A. van Kampen Netherlands
Christian Garzoni Switzerland
Jung‐Hyun Choi South Korea
Elitza S. Theel United States
Jingwen Ai China
Matthew J. Binnicker United States
Nicasio Mancini Italy
Matthew P. Cheng
Citations per year, relative to Matthew P. Cheng Matthew P. Cheng (= 1×) peers Nicasio Mancini

Countries citing papers authored by Matthew P. Cheng

Since Specialization
Citations

This map shows the geographic impact of Matthew P. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew P. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew P. Cheng more than expected).

Fields of papers citing papers by Matthew P. Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew P. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew P. Cheng. The network helps show where Matthew P. Cheng may publish in the future.

Co-authorship network of co-authors of Matthew P. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew P. Cheng. A scholar is included among the top collaborators of Matthew P. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew P. Cheng. Matthew P. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boodman, Carl, et al.. (2025). Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need. Clinical Infectious Diseases. 82(1). e193–e195.
2.
Lawandi, Alexander, Chelsea Caya, Todd C. Lee, et al.. (2025). Antibiotic synergy against Staphylococcus aureus : a systematic review and meta-analysis. Antimicrobial Agents and Chemotherapy. 69(8). e0119924–e0119924.
3.
Lenz, Joan Sesing, E. H. Belcher, Kaiwen Chen, et al.. (2025). Urine Cell-Free RNA vs Plasma Cell-Free RNA for Monitoring of Kidney Injury and Immune Complications. Clinical Chemistry. 71(10). 1058–1066.
4.
Mahshid, Sara, Tamer AbdElFatah, Dao Nguyen, et al.. (2024). Next-generation rapid phenotypic antimicrobial susceptibility testing. Nature Communications. 15(1). 9719–9719. 16 indexed citations
5.
6.
Prosty, Connor, Jesse Papenburg, Alexander Lawandi, et al.. (2024). Causal role of the gut microbiome in certain human diseases: a narrative review. SHILAP Revista de lepidopterología. 2(3). e100086–e100086. 5 indexed citations
7.
Caya, Chelsea, Matthew P. Cheng, Karen Colwill, et al.. (2023). Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID‐19 serological assays as a proof of concept. Vox Sanguinis. 118(12). 1069–1077. 2 indexed citations
8.
Prosty, Connor, Alex Nguyen, Mark Sorin, et al.. (2023). Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs. Blood Advances. 8(4). 857–866. 6 indexed citations
9.
Racine, Étienne, Guy Boivin, Yves Longtin, et al.. (2022). The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Influenza and Other Respiratory Viruses. 16(5). 916–925. 11 indexed citations
10.
Cheng, Alexandre Pellan, Matthew P. Cheng, Joan Sesing Lenz, et al.. (2022). Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proceedings of the National Academy of Sciences. 119(4). 29 indexed citations
11.
Fava, Vinicius M., Mathieu Bourgey, Marianna Orlova, et al.. (2022). A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. Science Advances. 8(22). eabm2510–eabm2510. 13 indexed citations
12.
Papenburg, Jesse, Matthew P. Cheng, Rachel Corsini, et al.. (2021). Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infectious Diseases. 8(6). ofab220–ofab220. 27 indexed citations
13.
Ward, Brian J., Philipe Gobeil, Annie Séguin, et al.. (2021). Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nature Medicine. 27(6). 1071–1078. 214 indexed citations breakdown →
14.
Chen, Kaiwen, Matthew P. Cheng, Anne McDonnell, et al.. (2021). Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis. Transplant Infectious Disease. 23(4). e13619–e13619. 9 indexed citations
15.
Gagnon, Michaël, Matthew P. Cheng, Steven Paraskevas, et al.. (2021). Kidney Transplantation in Times of Covid-19: Decision Analysis in the Canadian Context. Canadian Journal of Kidney Health and Disease. 8. 1014995532–1014995532. 4 indexed citations
16.
17.
Cheng, Matthew P., et al.. (2020). Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clinical Infectious Diseases. 72(9). e196–e203. 40 indexed citations
18.
Cheng, Matthew P., Cédric P. Yansouni, Nicole E. Basta, et al.. (2020). Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2. Annals of Internal Medicine. 173(6). 450–460. 91 indexed citations
19.
Russell, James A., John C. Marshall, Arthur S. Slutsky, et al.. (2020). Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open. 10(12). e040768–e040768. 3 indexed citations
20.
Vedula, Rahul S., Matthew P. Cheng, Dimitrios Farmakiotis, et al.. (2020). Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Advances. 5(1). 54–60. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicasio Mancini Breakdown of academic impact, for papers by Harald H. Kessler Breakdown of academic impact, for papers by Miki Nagao Breakdown of academic impact, for papers by Hee‐Chang Jang Breakdown of academic impact, for papers by Jeroen J. A. van Kampen Breakdown of academic impact, for papers by Christian Garzoni Breakdown of academic impact, for papers by Jung‐Hyun Choi Breakdown of academic impact, for papers by Elitza S. Theel Breakdown of academic impact, for papers by Jingwen Ai Breakdown of academic impact, for papers by Matthew J. Binnicker
Rankless by CCL
2026